X

Trial Profile

Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regorafenib (Primary)
Indications Colon cancer; Colorectal cancer; Rectal cancer
Focus Adverse reactions
Sponsors Bayer

Most Recent Events

20 Apr 2018 Status changed from active, no longer recruiting to completed.
21 Jan 2017 Results (Data cut off August 2015; n=787) of interim analysis assessing safety and efficacy of regorafenib, presented at the 2017 Gastrointestinal Cancers Symposium
06 Jan 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com